The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1355
Antiviral Drugs for Influenza
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Antiviral drugs can be used for treatment of patients with influenza and for prophylaxis when exposure to the disease occurs before or less than 2 weeks after vaccination. They can also be used to control institutional outbreaks of influenza.1 In recent years, the susceptibility of circulating influenza strains has evolved rapidly and treatment recommendations have changed during the influenza season. The CDC influenza web site provides frequently updated information on antiviral resistance (www.cdc.gov/flu).

NEURAMINIDASE INHIBITORS — Oseltamivir (Tamiflu), which is taken orally, and zanamivir (Relenza), which is inhaled, have generally been about 60-80% effective for prophylaxis after exposure to susceptible strains of seasonal influenza A or B. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Antiviral Drugs for Influenza
Article code: 1355b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian